GlassScriptPhysician profile
Marcus L Penn
NPI 1942287313
$4,263.93
in general payments reported to CMS, 2019-2025
34 companies · $768 in 2025
The $768 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $129 · 2021: $406 · 2022: $617 · 2023: $932 · 2024: $732 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.03 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.39 | 2019-2023 | |
| Exeltis, USA INC. | $400.09 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $391.77 | 2021-2025 | Acessa Provu System, Aptima, Myosure Tissue Removal Device |
| Baxter Healthcare | $346.15 | 2021-2025 | Tisseel |
| Astellas Pharma US INC | $339.05 | 2023-2025 | Veozah |
| Organon LLC | $221.52 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $213.41 | 2021-2022 | |
| Coopersurgical, INC. | $209.75 | 2019-2023 | Mara Console |
| Therapeuticsmd, INC. | $154.39 | 2019-2020 | |
| Pfizer INC. | $147.65 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.95 | 2019-2025 | |
| Sage Therapeutics, LLC | $110.13 | 2024-2025 | Zurzuvae |
| Ethicon US, LLC | $109.04 | 2024-2025 | Ethicon, Vistaseal, Evarrest |
| Sumitomo Pharma America, INC. | $105.65 | 2023-2025 | Myfembree |
| Myriad Women'S Health, INC. | $101.87 | 2023 | Myrisk |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $87.46 | 2022 | |
| Merck Sharp & Dohme LLC | $68.57 | 2019-2024 | Gardasil 9, Gardasil |
| Dysis Medical, INC. | $57.61 | 2021 | |
| Mayne Pharma Commercial LLC | $55.14 | 2025 | |
| Shield Therapeutics INC | $43.87 | 2023-2024 | Accrufer |
| Mylan Pharmaceuticals INC. | $34.51 | 2021 | |
| Allergan, INC. | $34.02 | 2019-2020 | |
| Aspira Women'S Health INC | $33.90 | 2023-2025 | Ova1 |
| Smith+Nephew, INC. | $28.57 | 2021-2023 | Pico 7, Acticoat 4" X 4" |
| Meditrina | $25.01 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $24.30 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $21.72 | 2019 | |
| Exact Sciences Corporation | $21.38 | 2023 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $19.53 | 2019 | |
| Novo Nordisk INC | $18.56 | 2025 | Wegovy |
| Millicent US INC | $18.04 | 2024 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $17.36 | 2025 | Solosec, Phexx, Phexxi |
| Optumhealth Care Solutions, LLC | $13.85 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Minerva Surgical, INC | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Penn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.